A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
Proceedings of MOL2NET'21, Conference on Molecular, Biomedical & Computational Sciences and Engineering, 7th ed.
The emergence of Multidrug-Resistant (MDR) strains promotes the improvement of Antibacterial Drugs (AD). Some nanoparticles (NP) may be AD carriers, but some have antibacterial activity per se. This opens a window of opportunity for the design of Dual Antibacterial Drug-Nanoparticle (DADNP) systems. DADNP discovery is a slow process due to the high number of combinations of NP vs. AD compounds, assays, etc.doi:10.3390/mol2net-07-11194 fatcat:lpfeabaoh5fs7anb5dig3zry4q